The drugs have been used to treat diabetes for a couple decades now, but with the realization that they can have a significant impact on weight loss, the interest in this class of medications has shot up
Can the device supply keep up with the demand
Self-reported questionnaires for anthropometrics, demographics, dietary habits, and GLP-1RA usage were administered
In preclinical studies, cotadutide demonstrated a more pronounced loss of body weight, reduction in food intake, and superior improvement in glycemic parameters in rodents compared to a GLP-1 RA
This increase would cover the projected net cost of $170 million ($143 million after rebates) for the 23,000+ plan participants using GLP-1s for weight loss, up from less than 3,000 participants in mid-2021
Take the clinical trials for Wegovy as an example: participants with type 2 diabetes lost an average of 3.9% of their body weight within three months, compared to 6.3% in those without diabetes